Immunohistochemistry Digital Breast Cancer Panel 3 Test
Short Name: IHC Digital Breast Cancer Panel 3
Immunohistochemistry Digital Breast Cancer Panel 3 Test test available at DNA Labs India for ₹0. Uses Immunohistochemistry, Digital Pathology on Tumour tissue in 10% Formal-saline or Formalin fixed paraffin embedded (FFPE) block samples. Results in Report available in 5-7 days, depending on sample type (block or tissue biopsy).. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr SHAILAJA RAGHUNATH MURDESHWAR
Consultant Physician · Reg: 8052
Last reviewed: September 7, 2026
Overview
The purpose of the Immunohistochemistry Digital Breast Cancer Panel 3 Test is to assess the expression of key biomarkers in breast cancer tissue: Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER-2). ER and PR status helps evaluate responsiveness to endocrine therapy, while HER-2 expression indicates suitability for targeted therapies like Herceptin. The test includes digital photomicrograph analysis and pathologist review for the presence of malignant cells, ensuring accurate diagnosis, staging, and guidance for treatment decisions in breast cancer patients.
- Test Code
- 892
- Sample Type
- Tumour tissue in 10% Formal-saline or Formalin fixed paraffin embedded (FFPE) block
- Result Time
- Report available in 5-7 days, depending on sample type (block or tissue biopsy).
- Fasting Required
- No
- Method
- Immunohistochemistry, Digital Pathology
Sample Collection
Ensure the tumour tissue is properly collected via biopsy. Provide a copy of the histopathology report, indicate the biopsy site, and share relevant clinical history with the healthcare provider.
Method: Tissue biopsy collection
Laboratory Analysis
Standard tissue biopsy procedure performed by a healthcare professional, with the sample preserved in 10% formal-saline or as an FFPE block.
Report Delivery
The tissue sample is shipped at room temperature to DNA Labs India for immunohistochemistry analysis and digital reporting.
Timeline: Report available in 5-7 days, depending on sample type (block or tissue biopsy).
Patient Instructions
About This Test
Who Should Get This Test
The purpose of the Immunohistochemistry Digital Breast Cancer Panel 3 Test is to assess the expression of key biomarkers in breast cancer tissue: Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER-2). ER and PR status helps evaluate responsiveness to endocrine therapy, while HER-2 expression indicates suitability for targeted therapies like Herceptin. The test includes digital photomicrograph analysis and pathologist review for the presence of malignant cells, ensuring accurate diagnosis, staging, and guidance for treatment decisions in breast cancer patients.
How to Prepare
- Submit tumour tissue in 10% Formal-saline or as a Formalin fixed paraffin embedded (FFPE) block
- Ship the sample at room temperature
- Provide a copy of the histopathology report
- Indicate the site of biopsy
- Provide relevant clinical history
Doctor's Notes
Reviewed by Dr SHAILAJA RAGHUNATH MURDESHWAR — MBBS, MD (General Medicine) · Reg. No. 8052
"This test is essential for determining hormone receptor status (ER, PR) and HER-2 expression in breast cancer, guiding targeted therapy decisions and improving patient outcomes."
Last medically reviewed: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Poorly fixed or degraded tissue
- Insufficient tissue quantity for analysis
- Missing or incomplete clinical information
Understanding Your Results
Consult your oncologist or healthcare provider if you experience symptoms of breast cancer, such as a lump, breast changes, or nipple discharge, or for follow-up after diagnosis to discuss test results and treatment options.
Limitations
- ⚠Results depend on tissue quality and sample adequacy
- ⚠HER-2 equivocal results (2+) may require additional fluorescence in situ hybridization (FISH) testing
- ⚠Test does not detect all genetic mutations associated with breast cancer
Risks & Considerations
- ●Minimal risks associated with biopsy collection, such as infection, bleeding, or discomfort at the biopsy site
- ●No direct risks from the immunohistochemistry test itself
Interfering Factors
- ●Poor tissue fixation or preservation
- ●Insufficient or inadequate tissue sample
- ●Technical errors in immunohistochemistry processing
Frequently Asked Questions
What is the Immunohistochemistry Digital Breast Cancer Panel 3 Test?
Why is this test important for breast cancer patients?
What sample is required for this test?
How is the test performed?
What do the results mean?
How long does it take to get results?
Is home sample collection available?
What is the cost of this test?
Are there any risks associated with this test?
Can this test detect all types of breast cancer?
How should I prepare for the test?
What if my HER-2 result is equivocal?
Related Tests
Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.